The Health Secretary accepts a recommendation from a parliamentary committee regarding prostate cancer screening. The committee’s position is that routine screening of all men using prostate specific antigen (PSA) testing is not justified because it could cause more harm than benefit. The reporting notes that the decision is viewed negatively by campaigners who support broader PSA-based screening, but it follows the committee’s assessment of the potential downsides associated with PSA screening at a population level. Those downsides are presented as outweighing the expected gains when screening is applied to all men, rather than targeted approaches. While the sources provided focus on the acceptance of the committee’s recommendation and the committee’s reasoning, they do not specify in detail what the final screening policy will require beyond rejecting universal PSA screening. Overall, the decision reflects a shift toward a more cautious approach, based on the committee’s view that not all men should receive PSA tests as a standard measure due to the risk of harm.